News and Trends 16 Jul 2024
German biotech raises $150M on its way to tackle cancer therapy resistance
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.
News and Trends
- Latest Posts
More News! 11 Jul 2024
CDMO trends post-Wuxi’s exit from the US: who will take its place?
The BIOSECURE Act is reshuffling the deck and Indian CDMOs are looking good. Discover the trends in this evolving landscape.
More News! 27 May 2024
New report shows that Swiss biotech capital investment surged last year
With a record revenue of $8 billion in 2023, Swiss biotech appears robust in 2024. Delve into the findings of the Swiss Biotech Report 2024.
News and Trends 18 Apr 2024
Biotech under surveillance: The global impact of the WuXi AppTec controversy
Delve into the ongoing controversy involving the Chinese company WuXi AppTec and the possible impact on U.S. national security measures.
News and Trends 1 Feb 2024
Can gene therapy be the key to restoring hearing loss?
Explore gene therapy’s success in treating genetic hearing loss as a child regains hearing at the Children’s Hospital of Philadelphia.
News and Trends 18 Jan 2024
2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year
Here are some of the key takeaways from the JPM Healthcare Conference that lay the groundwork for what we can expect in 2024.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 12 Jan 2024
AI and a brain organoid: can this combo take on supercomputers?
Explore the groundbreaking fusion of brain organoids and AI in the creation of Brainoware, the world’s first biohybrid computer.
News and Trends 8 Jan 2024
Is the biotech industry poised for recovery in 2024?
The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery.
News and Trends 21 Dec 2023
The big pharma race against deadly RSV steps up in 2023
GSK and Pfizer received FDA approval for their RSV vaccines in 2023. Now, AstraZeneca has joined the race with its latest acquisition.
News and Trends 7 Dec 2023
BIO-Europe 2023: top ten highlights
The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with our parent company, life science […]
News and Trends 6 Dec 2023
A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy
Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]
News and Trends 1 Dec 2023
Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered
Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]
ADVERTISEMENT
